ML
MRCHEVELI

მრჩეველი – ლიმბახის დიაგნოსტიკის ევროპული ჯგუფი

EUROPEAN LIMBACH DIAGNOSTIC GROUP

9, Al. Kazbegi ave. 0160 Tbilisi, Georgia tel: +995 32 370071 fax: +995 32 378848 info@mrcheveli.com www.mrcheveli.com თბილისი, 0160, ალ. ყაზბეგის გამზ. 9

Patient: I.K.

DOB: 24.03.1953

Sex: Male

Diagnosis:

B18.2 Chronic HCV
B18.1 Chronic HBV without Delta agent
K78 Liver Cirrhosis (Child Pugh B, 8)

Medical history:

In 2012 patient was diagnosed with chronic HBV/HCV co-infections. He did not do regular medical follow-up. On 04/30/2015 he came to our clinic. He refused excessive alcohol consumption or illicit drug use.
He suffered with somnolence, nasal bleeding, ankle swelling.
Physical examination revealed – stigmata of liver cirrhosis (palmar erythema, spider angioma), mild hepatic encephalopathy (asterixis); ascites was absent.
According to additional diagnostic investigations, he was diagnosed to have chronic HCV/HBV related liver cirrhosis (Child Pugh B, 8 points).
Patient started antiviral treatment in C virus elimination program:
Sofosbuvir – 400mg/d;
Ribavirin – 1200 mg/d;
Planed duration of treatment 48 weeks.

From 4th week of treatment worsened memory problems, insomnia. rifaximin – 200mg TD was added.

On 10/30/2015 (19th week of treatment) due to shortness of breath, chest pain and high fever patient admitted to other hospital. Pneumonia and pleural empyema was diagnosed and conducted antimicrobial therapy and additional supportive treatment. On 5th November patient was discharged. He had no fever.
Due to the severe weakness ribavirin dose reduced to 800 mg/d.
Treatment has stopped at 24 weeks of treatment.

Currentely continuing outpatient follow-up with infectionist in another clinic.

mL
MRCHEVELI
მრჩეველი – ლიმბახის დიაგნოსტიკის ევროპული ჯგუფი
EUROPEAN LIMBACH DIAGNOSTIC GROUP
9, Al. Kazbegi ave. 0160 Tbilisi, Georgia tel: +995 32 370071 fax: +995 32 378848 info@mrcheveli.com www.mrcheveli.com თბილისი, 0160, ალ. ყაზბეგის გამზ. 9

Diagnostic result:

Before treatment (May 2015):

BIL(tot.) mg/dl	BIL(dir.) mg/dl	ALT U/L	AST U/L	GGT U/L	ALP U/L	TP g/l	Alb. g/l	Glucose (f.) mg/dl	Crea. mg/dl	AFP mkg/l
2.3	1.6	53	82	31	145		32	76	0.77	32

CBC: WBC – 6.01/nl, HGB – 13.4g/dl, PLT - 66/nl;
FIB-4 = 11.26.
PT – 51%, INR – 1.58.
HBsAg (+) (PCR HBV DNA – was not done)
Anti-HBs - <10 U/L; ANA < 80.
PCR HCV-RNA – 186 000 IU/ml;
HCV-genotype – 2k/1b (recombinant form).
US: cirrhotic liver, moderate splenomegaly.
CT abdomen: nodular liver, no signs of HCC.

4 weeks of treatment:
PCR HCV-RNA – undetectable;

20 weeks of treatment:

BIL(tot.) mg/dl	BIL(dir.) mg/dl	ALT U/L	AST U/L	Alb. g/l	Crea. mg/dl
3.1	1.2	36	64	32	0.77

CBC: WBC – 12.4/nl, HGB – 12.7g/dl, PLT - 132/nl;

Current medications:

Rifaximin (200 mg. TD), Lactulose

Dr. Mamuka Zakalashvili

Dr. Jaba Zarkua

Dr. Davit Metreveli

03.12.2015